PDQ6: Loss of adiponectin as a contributing factor in cancer cachexia

PDQ6：脂联素丢失是癌症恶病质的一个促成因素

基本信息

批准号：
8687301
负责人：
MARTHA A BELURY
金额：
$ 19.76万
依托单位：
OHIO STATE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2014
资助国家：
美国
起止时间：
2014-05-01 至 2016-04-30
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/8687301
关键词：
Adipocytes Adipose tissue Anorexia Binding Biogenesis Biological Markers Body Weight Body Weight decreased Cachexia Cancer Model Cessation of life Clinical Treatment Colon Disease Energy Metabolism Goals Homeostasis Inflammation Inflammatory Insulin Resistance Interleukin-6 Limb structure Link Lipids MAP Kinase Gene MAPK14 gene MAPK3 gene Malignant Neoplasms Metabolic Metabolism Mitochondria Mus Muscle Muscle Cells Muscle Fibers Muscle Proteins Muscle function Obesity Pathogenesis Pathway interactions Patients Physiological Plasma Plasma Proteins Proteins Quality of life Regulation Relative (related person)Reporting Research Role Serum Signal Pathway Signal Transduction Skeletal Muscle Staging Time Tissues Work adenylate kinase adipokines adiponectin cancer therapy cytokine effective therapy energy balance functional status improved insulin sensitivity mortality mouse model muscle form muscle regeneration muscle strength novel outcome forecast oxidation protein degradation public health relevance receptor repaired response restoration tumor tumor growth tumor progression

项目摘要

DESCRIPTION (provided by applicant): Nearly one third of cancer deaths may be attributed to cachexia. Factors that contribute to this unintended weight loss include anorexia, deranged energy metabolism, and elevated inflammation. While the loss of skeletal muscle mass predicts for poor prognosis and reduced quality of life, it is the loss of adipose tissue that is the strongst predictor for mortality in patients with cachexia. Because of the strong relationship of adipose loss with mortality, and because adipose mass declines early in the pathogenesis of cancer cachexia, mitigating adipose loss could be a useful strategy for slowing the progression of cachexia. In mice, tumor-induced loss of adipose mass occurs coincident with loss of adipocyte function including an inability to store lipid and to secrete adipokines. The adipokine, adiponectin, may be of great importance since it is known to modulate inflammation and metabolism. In a mouse model of cancer cachexia, adiponectin decreases in a time dependent manner. Importantly for cachexia, adiponectin decreases inflammation, improves insulin sensitivity and increases b-oxidation through mitochondrial biogenesis in skeletal muscle. Our central hypothesis is that loss of adiponectin is a key driver of the pathogenesis of cancer cachexia. In Aim #1, we will examine the ability of adiponectin to alter physiologic and metabolic aspects of cancer cachexia. In Aim #2, we will determine the effect of adiponectin on biomarkers of skeletal muscle regeneration in mice with cancer cachexia. Effective therapies for treating cancer cachexia are lacking. Research outlined in this proposal is significant because it will probe the role of adiponectin, a cytokine that decreases inflammation and modulates metabolism, the loss of which is a driver of muscle loss. These studies should provide a mechanistic link between the loss of adipose tissue with the loss of muscle that contributes to mortality from cancer cachexia. Our long-term goal is to develop novel clinical treatments to improve functional status, quality of life, and survival for patients with cancer cachexia.

描述（由申请人提供）：近三分之一的癌症死亡可能归因于恶病质。导致这种意外体重减轻的因素包括厌食、能量代谢紊乱和炎症加剧。虽然骨骼肌质量的丧失预示着预后不良和生活质量下降，但脂肪组织的丧失是恶病质患者死亡率的最强预测因素。由于脂肪减少与死亡率密切相关，并且由于脂肪量在癌症恶病质发病机制的早期下降，因此减轻脂肪减少可能是减缓恶病质进展的有效策略。在小鼠中，肿瘤引起的脂肪量减少与脂肪细胞功能的丧失同时发生，包括无法储存脂质和分泌脂肪因子。脂肪因子脂联素可能非常重要，因为已知它可以调节炎症和新陈代谢。在癌症恶病质小鼠模型中，脂联素以时间依赖性方式减少。对于恶病质来说，脂联素可以减少炎症，提高胰岛素敏感性，并通过骨骼肌中的线粒体生物发生增加 b-氧化。我们的中心假设是脂联素的丧失是癌症恶病质发病机制的关键驱动因素。在目标#1中，我们将检查脂联素改变癌症恶病质的生理和代谢方面的能力。在目标#2中，我们将确定脂联素对癌症恶病质小鼠骨骼肌再生生物标志物的影响。缺乏治疗癌症恶病质的有效疗法。该提案中概述的研究意义重大，因为它将探讨脂联素的作用，脂联素是一种减少炎症和调节新陈代谢的细胞因子，脂联素的丧失是肌肉损失的驱动因素。这些研究应该提供脂肪组织损失与肌肉损失之间的机制联系，而肌肉损失导致癌症恶病质导致的死亡。我们的长期目标是开发新的临床治疗方法，以改善癌症恶病质患者的功能状态、生活质量和生存率。